Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Product Pipeline Our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza, and Ebola virus (EBOV). We also have additional preclinical stage programs, including the Middle East Respiratory Syndrome coronavirus (MERS). Corporate Overview Novavax is headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Type
Public
HQ
Gaithersburg, US
Founded
1987
Size (employees)
355 (est)-19%
Novavax was founded in 1987 and is headquartered in Gaithersburg, US

Novavax Office Locations

Novavax has offices in Gaithersburg, Rockville and Uppsala
Gaithersburg, US (HQ)
20 Firstfield Rd
Uppsala, SE
109 Kungsgatan
Rockville, US
9920 Belward Campus Dr

Novavax Data and Metrics

Novavax Financial Metrics

Novavax's revenue was reported to be $15.4 m in FY, 2016 which is a 58% decrease from the previous period.
USD

Revenue (FY, 2016)

15.4 m

Revenue growth (FY, 2015 - FY, 2016), %

(58%)

Net income (FY, 2016)

(280 m)

EBIT (FY, 2016)

(269.1 m)

Market capitalization (26-Jun-2017)

336.3 m

Closing share price (26-Jun-2017)

1.2

Cash (31-Dec-2016)

144.4 m
Novavax's current market capitalization is $336.3 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

20.9 m30.7 m36.3 m15.4 m

Revenue growth, %

(5%)47%18%(58%)

R&D expense

50.3 m79.4 m162.6 m237.9 m

General and administrative expense

14.8 m19.9 m30.8 m46.5 m

Operating expense total

73.3 m114.4 m193.5 m284.5 m

EBIT

(52.4 m)(83.7 m)(157.2 m)(269.1 m)

EBIT margin, %

(251%)(273%)(434%)(1753%)

Interest expense

(160 k)(157 k)(241 k)(13 m)

Interest income

187 k286 k660 k2.1 m

Net Income

(52 m)(82.9 m)(156.9 m)(280 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

119.5 m32.3 m93.1 m144.4 m

Accounts Receivable

1.9 m7.5 m2.3 m233 k

Inventories

9.2 m19.3 m21.8 m

Current Assets

145 m188.2 m287.3 m287.8 m

PP&E

14.3 m19.7 m32.3 m40.2 m

Goodwill

59.5 m54.6 m53.1 m51.7 m

Total Assets

235.9 m276 m386 m394.3 m

Accounts Payable

6 m12.9 m11.9 m5.7 m

Current Liabilities

18.9 m34.1 m76.5 m66.4 m

Additional Paid-in Capital

612.9 m729.4 m951.6 m936 m

Retained Earnings

(410.1 m)(493.1 m)(650 m)(930 m)

Total Equity

203.2 m229.6 m292.7 m(5.5 m)

Financial Leverage

1.2 x1.2 x1.3 x-71.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(52 m)(82.9 m)(156.9 m)(280 m)

Depreciation and Amortization

2.6 m4.4 m6 m8.5 m

Accounts Receivable

2.1 m

Accounts Payable

4.2 m14 m9.1 m(4.8 m)

Cash From Operating Activities

(45.4 m)(87.1 m)60.8 m(255.5 m)

Capital Expenditures

(5.8 m)(7.3 m)(18.3 m)(18.2 m)

Cash From Investing Activities

16.4 m(129.8 m)(21.3 m)28 m

Short-term Borrowings

(473 k)(671 k)(395 k)(600 k)

Cash From Financing Activities

131 m109.7 m208.3 m279 m

Free Cash Flow

(51.1 m)(94.4 m)42.5 m(273.7 m)
USDY, 2016

Revenue/Employee

34.7 k

Financial Leverage

-71.1 x

Novavax Operating Metrics

FY, 2016

Patents (US)

250

Phase II Trials

1

Phase III Trials

1

Phase I Trials

2

Phase Preclinical

3

Novavax Market Value History

Novavax Job Categories

Novavax Median Salaries

Source: 30 public H-1B filings from Novavax

Novavax Online and Social Media Presence

Novavax Company Life and Culture

You may also be interested in